Skip to main content
Terug
Watch Compare

Cardiff Oncology, Inc.

Datakwaliteit: 100%
CRDF
Nasdaq Manufacturing Chemicals
€ 1,58
▼ € 0,09 (-5,39%)
Marktkapitalisatie: 114,85 M
Prijs
€ 1,68
Marktkapitalisatie
114,85 M
Dagbereik
52-Weeksbereik
Volume
Openen —
50D / 200D Gem.
50D / 200D Gem.

Quick Summary

Belangrijkste Punten

Revenue grew 13,37% annually over 5 years — strong growth
Negative free cash flow of -37,97 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 26,55%
Capital efficient — spends only 7,42% of revenue on capex

Groei

Revenue Growth (5Y)
13,37%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)-13,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-85,39%
Onder sectorgemiddelde (-53,47%)
ROIC-71,53%
Net Margin-7732,04%
Op. Margin-8256,32%

Veiligheid

Debt / Equity
N/A
Current Ratio4,20
Interest CoverageN/A

Waardering

PE (TTM)
-2,50
Onder sectorgemiddelde (-1,48)
P/B Ratio2,35
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,5 -1,5
P/B 2,4 1,6
ROE % -85,4 -53,5
Net Margin % -7732,0 -41,5
Rev Growth 5Y % 13,4 1,8
D/E 0,3

Koersdoel Analisten

8 analisten
Buy
Huidig
€ 1,58
+390.5%
Koersdoel
€ 7,75
€ 2,00
€ 9,25
€ 12,00
Vooruitzicht
Forward K/W -2,26
Forward WPA -€ 0,70
Omzet Sch. 246.430,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,70
-€ 0,83 – -€ 0,59
246.430,0 4
FY2026 -€ 0,52
-€ 0,67 – -€ 0,37
338.890,0 5

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,20 -€ 0,11 +44,1%
Q32025 -€ 0,21 -€ 0,17 +18,4%
Q22025 -€ 0,20 -€ 0,21 -6,8%
Q12025 -€ 0,19 -€ 0,20 -7,5%

ETFs Holding This Stock

IRSIX IRSIX
0,01% weight
IIRSX IIRSX
0,01% weight
IRCIX IRCIX
0,01% weight
VVICX VVICX
0,01% weight
IRSSX IRSSX
0,01% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y) -13,18% Revenue Growth (3Y) 10,23%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13,37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 593.000,0 Net Income (TTM) -45,85 M
ROE -85,39% ROA -65,73%
Gross Margin N/A Operating Margin -8256,32%
Net Margin -7732,04% Free Cash Flow (TTM) -37,97 M
ROIC -71,53% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,20
Interest Coverage N/A Asset Turnover 0,01
Working Capital 47,10 M Tangible Book Value 48,79 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,50 Forward P/E N/A
P/B Ratio 2,35 P/S Ratio 193,68
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -33,06%
Market Cap 114,85 M Enterprise Value 104,72 M
Per Share
EPS (Diluted TTM) -0,69 Revenue / Share 0,01
FCF / Share -0,56 OCF / Share -0,55
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 7,42% FCF Conversion 82,81%
SBC-Adj. FCF -43,65 M Growth Momentum -26,55

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 593.000,0 683.000,0 488.000,0 386.000,0 359.000,0
Net Income -45,85 M -45,43 M -41,44 M -38,70 M -28,29 M
EPS (Diluted) -0,69 -0,95 -0,93 -0,89 -0,73
Gross Profit
Operating Income -48,96 M -48,65 M -45,41 M -39,90 M -28,86 M
EBITDA
R&D Expenses 27,10 M 17,40 M
SG&A Expenses 14,22 M 12,48 M 13,04 M 13,18 M 11,84 M
D&A 364.000,0 404.000,0 398.000,0 236.000,0 451.000,0
Interest Expense 0,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 61,88 M 97,19 M 81,64 M 116,19 M 149,54 M
Total Liabilities 16,50 M 14,24 M 11,90 M 9,85 M 9,13 M
Shareholders' Equity 45,39 M 82,95 M 69,74 M 106,34 M 140,42 M
Total Debt
Cash & Equivalents 17,47 M 51,47 M 21,66 M 16,35 M 11,94 M
Current Assets 60,13 M 95,05 M 77,41 M 111,28 M 146,13 M
Current Liabilities 16,39 M 13,43 M 10,44 M 7,81 M 6,56 M